RenovoRx develops RenovoCath, a drug delivery device, and other drug and device combination products for healthcare providers. RNXT reports earnings on Thu, Nov 5, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Aug 28 | Ascendiant Capital | Target raised | Buy | |
| Jun 1 | Ascendiant Capital | Maintained | Buy |
Seasonality
How RNXT has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.
Whale Options Flow
90DNo whale options trades in RNXT in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether RNXT is in one of them and how their past RNXT trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered RNXT in an article yet. Here's the latest on the wider market.
About RenovoRx
RenovoRx is a medical device company based in Mountain View, California. It develops RenovoCath, a proprietary drug delivery device sold as a standalone product, along with other products that combine drugs and devices. Its product candidates are still in clinical trials. Its customers are expected to include physicians, hospitals and other healthcare providers, whose care may be paid for by government programs and private insurers.
- Headquarters
- Mountain View, CA